Posted by Michael Wonder on 13 Dec 2024
Stoke Therapeutics receives FDA breakthrough therapy designation for zorevunersen for the treatment of Dravet syndrome
4 December 2024 - Supported by evidence from clinical studies that indicate that zorevunersen may demonstrate substantial improvement over available therapies.
Stoke Therapeutics today announced that it has received breakthrough therapy designation from the US FDA for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation, not associated with gain of function, in the SCN1A gene.
